PharmaEngine

PharmaEngine FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 445.40 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 26.00 % — a change of 1,612.91% (higher).

FCF Conversion

445.40 %

YoY

1,612.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of PharmaEngine is 2025 445.40 % . FCF Conversion Rate (FCF/EBITDA) of PharmaEngine was 2024 26.00 % . It decreases by 1,612.91% higher compared to the previous year.

The PharmaEngine FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
575.68 TWD
Jan 1, 2019
37.30 TWD
Jan 1, 2020
10.62 TWD
Jan 1, 2021
218.16 TWD
Jan 1, 2022
62.13 TWD
Jan 1, 2023
93.21 TWD
Jan 1, 2024
26.00 TWD
Jan 1, 2025
445.40 TWD
The PharmaEngine FCF Conversion history
YEARFCF ConversionYoY
445.40 %+1,612.91%
26.00 %-72.10%
93.21 %+50.02%
62.13 %-71.52%
218.16 %+1,954.70%
10.62 %-71.53%
37.30 %-93.52%
575.68 %-755.77%
-87.79 %-169.65%
126.05 %+13.86%
110.70 %+4.45%
105.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

FCF Conversion Rate (FCF/EBITDA) of PharmaEngine is 445.40 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of PharmaEngine changed from 26.00 % to 445.40 %, representing a 1,612.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s PharmaEngine with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmaEngine

All Key Metrics — PharmaEngine